In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk

ACP Journal ClubSeptember 2023In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wkCatherine Rowan, MB BCH BAO, MDCatherine Rowan, MB BCH BAO, MDUniversity of Calgary, Calgary, Alberta, Canada (C.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J23-0069 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLoftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. https://pubmed.ncbi.nlm.nih.gov/37224198Clinical Impact RatingsGIM/FP/GP: Gastroenterology: References1. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-2128. [PMID: 35644166] Google Scholar2. U.S. Food and Drug Administration. Rinvoq: highlights of prescribing information. Accessed at www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s015lbl.pdf on 17 Jul 2023. Google Scholar Author, Article, and Disclosure InformationAuthors: Catherine Rowan, MB BCH BAO, MDAffiliations: University of Calgary, Calgary, Alberta, Canada (C.R.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0069.This article was published at Annals.org on 5 September 2023.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics September 2023Volume 176, Issue 9Page: JC103KeywordsBiologicsCrohn's diseaseDrug therapyPatientsQuality of lifeSafetySteroidsThrombosisUlcerative colitis ePublished: 5 September 2023 Issue Published: September 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...